Predictive Factors for Non-sentinel Lymph Node Metastasis of Breast Cancer

Year 2025, Volume: 15 Issue: 2, 357 - 361, 30.06.2025

İbrahim Ali Özemir , Muhammet Ali Aydemir , Leyla Zeynep Tigrel , Hakan Baysal

https://doi.org/10.33808/clinexphealthsci.1190227

Abstract

Objective: The indications for axillary dissection after sentinel lymph node biopsy (SLNB) in breast cancer (BC) is gradually decreasing, even for selected patients with positive SLNB. Increased predictability of Non-sentinel lymph node (Non-SLN) metastasis could prevent unnecessary axillary dissection and even eliminate the need for SLNB. In this study we aimed to investigate the clinical and the pathological factors that affect Non-SLN metastasis.
Methods: Early breast cancer patients who underwent SLNB between 2013 and 2018 were retrospectively included in the study. Patients were divided into 3 groups; Group-1 SLNB negative patients, Group-2 SLNB positive but Non-SLN negative patients and Group-3 both SLNB and non-SLN positive patients. Groups were compared in terms of demographic data, tumor size, SLN size, Ki-67 percentages, and hormone receptor status.
Results: Seventy-six (36.4%) out of 206 patients had positive SLNB. Non-SLN metastases were detected in 33 (42.7%) patients. Mean tumor size found significantly higher in Group 3 (Group-1, 2 and 3 respectively; 20.5±9.7mm, 21.9±9.3mm, 25.1±9.5mm; p<.01). The mean SLN size was significantly bigger in Group-3 (Group-1, 2 and 3 respectively, 13.1±5.6mm, 13.9±8.2mm, 16.8±6.5mm; p<.01). Rate of patients with Ki-67 index higher than 14% was 84.3% in Group-3, 59.1% in Group-2 and 49.2% in Group-1(p<.01). A statistically significant difference was not detected between the groups in terms of hormone receptor status.
Conclusion: Tumor size, SLN size and Ki-67 percentages have importance in predicting the presence of Non-SLN metastasis in BC patients. These factors should also be taken into account for the management of the axillary metastasis and adjuvant treatment for BC.

Keywords

Breast cancer , Non-sentinel lymph node , Lymph node metastasis

Ethical Statement

This study was approved by Ethics Committee of İstanbul Medeniyet University Göztepe Prof. Dr. Süleyman Yalçın City Hospital (Approval date: 30.12.2014; Number: 2014/0200)

Supporting Institution

-

Project Number

-

Thanks

-

References

• Lucci A, McCall LM, Beitsch PD, Whitworth PW, Reintgen DS, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Giuliano AE. Surgical complications associated with sentinel lymph node dissection plus axillary lymph node dissection compared with sentinel lymph node dissection alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol. 2007;25(24):3657–3663. https://doi.org/10.1200/JCO.2006.07.4062
• Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: The ACOSOG Z0011 (Alliance) randomized clinical trial. JAMA. 2017;318(10):918–926. https://doi.org/10.1001/jama.2017.11470
• Gill PG, SNAC Trial Group of the Royal Australasian College of Surgeons and NHMRC Clinical Trials Centre. Sentinel-lymph-node-based management or routine axillary clearance? One-year outcomes of sentinel node biopsy versus axillary clearance (SNAC): A randomized controlled surgical trial. Ann Surg Oncol. 2009;16(2):266–275. https://doi.org/10.1245/s10434-008-0229-z
• Nemoto T, Natarajan N, Bedwani RN, Vana J, Murphy GP. Management and survival of female breast cancer: results of a national survey by the American College of Surgeons. Cancer. 1980;45(12):2917–2924. https://doi.org/10.1002/1097-0142
• Abdessalam SF, Krag DN, Degnim AC, Anderson SJ, Julian TB, Harlow SP, Weaver DL, Mamounas EP, Costantino JP, Wolmark N. Predictors of positive axillary lymph nodes after sentinel lymph node biopsy in breast cancer. Am J Surg. 2001;182(4):316–320. https://doi.org/10.1016/S0002-9610
• Rouzier R, Coutant C, Barranger E, Uzan S, Darai E, Reyal F, Bollet MA, Vincent-Salomon A, Delaloge S, Mathieu MC, Fourchotte V, Antoine M, Alran S, Salmon RJ, Campana F, Lerebours F, Mazouni C, Cottu PH, Pierga JY, Giacchetti S, Dendale R, Asselain B, Sastre-Garau X, Spielmann M. Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study. Br J Cancer. 2017;116(9):1135–1140. https://doi.org/10.1038/bjc.2017.81
• Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155–168.
• Gnant M, Harbeck N, Thomssen C. St. Gallen 2011: summary of the consensus discussion. Breast Care (Basel). 2011;6(2):136–141. https://doi.org/10.1159/000327001
• Harbeck N, Thomssen C, Gnant M. St. Gallen 2013: Brief preliminary summary of the consensus discussion. Breast Care (Basel). 2013;8(2):102–109. https://doi.org/10.1159/000351193
• Krag DN, Anderson SJ, Julian TB, Brown AM, Harlow SP, Costantino JP, Ashikaga T, Weaver DL, Mamounas EP, Jalovec LM, Frazier TG, Noyes RD, Robidoux A, Scarth HM, Wolmark N. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: Overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–933. https://doi.org/10.1016/S1470-2045(10)70207-2
• Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, Saha S, Hunt KK, Morrow M, Ballman K. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg. 2010;252(3):426–432. https://doi.org/10.1097/SLA.0b013e3181f08f32
• Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Morrow M, McCall L. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA. 2011;305(6):569–575. https://doi.org/10.1001/jama.2011.90.
• Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Duez N, Rutgers EJ, Terzolo M, van der Velde CJ, Bogaerts J, Bartelink H, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): A randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014;15(12):1303–1310. https://doi.org/10.1016/S1470-2045(14)70460-7.
• Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(5):561–564. https://doi.org/10.1200/JCO.2016.71.0947.
• Galimberti V, Cole BF, Zurrida S, Viale G, Luini A, Veronesi P, Paganelli G, Maisonneuve P, Gatti G, Intra M, Veronesi U. Axillary dissection versus no axillary dissection in patients with sentinel-node micrometastases (IBCSG 23-01): A phase 3 randomised controlled trial. Lancet Oncol. 2013;14(4):297–305. https://doi.org/10.1016/S1470-2045(13)70035-4.
• Solà M, Alberro JA, Fraile M, Santesteban P, Ramos M, Fabregat X, Vidal MC, Santamaría G, Galve N, Alarcón J, Pons F, Farrús B, Muñoz M, Urrutia G, Belmonte R, Guma A, Pons J, Ferrer J, Viñolas N, Lloveras B, Biete A, Gavilá J, Lluch A, Barnadas A, Muñoz M, Bellet M, Lloveras B, Viñolas N, Biete A. Complete axillary lymph node dissection versus clinical follow-up in breast cancer patients with sentinel node micrometastasis: final results from the multicenter clinical trial AATRM 048/13/2000. Ann Surg Oncol. 2013;20(1):120–127. https://doi.org/10.1245/s10434-012-2569-5.
• Mikami Y, Adachi S, Yamamoto S, Iwata H, Takashima T, Kuroi K, Kinoshita T, Iwata H, Takashima T, Kuroi K, Kinoshita T. Predicting nonsentinel lymph node metastasis in breast cancer: A multicenter retrospective study. J Surg Res. 2021;264:45–50. https://doi.org/10.1016/j.jss.2021.02.003.
• van la Parra RF, Peer PG, Ernst MF, Bosscha K. Meta-analysis of predictive factors for non-sentinel lymph node metastases in breast cancer patients with a positive sentinel lymph node. Eur J Surg Oncol. 2011;37(4):290–299. https://doi.org/10.1016/j.ejso.2011.01.004.
• Maimaitiaili A, Wu D, Liu Z, Wang S, Zhang Y, Li J, Zhang Y, Li J. Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients. Cancer Biol Med. 2018;15(3):282–289. https://doi.org/10.20892/j.issn.2095-3941.201.
• Hwang RF, Krishnamurthy S, Hunt KK, Mirza N, Ames FC, Feig BW, Ross MI, Singletary SE. Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol. 2003;10(3):248–254. https://doi.org/10.1245/aso.2003.03.060.
• Van Zee KJ, Manasseh DM, Bevilacqua JL, Boolbol SK, Tan LK, Cody HS 3rd, Brogi E, Borgen PI. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol. 2003;10(10):1140–1151. https://doi.org/10.1245/aso.2003.02.007.
• Degnim AC, Reynolds C, Pantvaidya G, Zakaria S, Hoskin TL, Boughey JC, Nascimento AG, Suman VJ, Halyard MY, McLaughlin SA, Grant CS, Donohue JH. Nonsentinel node metastasis in breast cancer patients: Assessment of an existing and a new predictive nomogram. Am J Surg. 2005;190(4):543–550. https://doi.org/10.1016/j.amjsurg.2005.06.036.
• Barranger E, Coutant C, Flahault A, Delpech Y, Darai E, Uzan S. An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat. 2005;91(2):113–119. https://doi.org/10.1007/s10549-004-7760-6
• Pal A, Provenzano E, Duffy SW, Pinder SE, Purushotham AD. A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg. 2008;95(3):302–309. https://doi.org/10.1002/bjs.6018.
• Kohrt HE, Olshen RA, Bermas HR, Goodson WH 3rd, Wood WW, Henry S, Tellez MR, Dirbas FM, Leong SP, Livermore TM, Carlson RW, Jeffrey SS. New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer. 2008;8:66. https://doi.org/10.1186/1471-2407-8-66.